TrialBlood2021

Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion and/or TP53 mutations.

Mariela Sivina et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.